Plum Alley Investments

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.

Einride is focused on intelligent movement, leveraging technology to optimize freight transport and logistics.

InnerPlant creates plants that communicate so farmers can make the best management decisions possible with data tied directly to plant physiology.

Gametogen is focused on innovative therapies for reproductive health, including treatments for menopause and embryology solutions.

FidoCure® is a proprietary canine cancer-care service developed by One Health Company, delivering advanced diagnostics and personalized therapeutics for dogs with cancer.

Air Protein produces a versatile super protein made from air, water, and energy, aiming to create sustainable food ingredients through landless agriculture.

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines enabled by hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases.

The world's first & most advanced wastewater intelligence platform that transforms wastewater infrastructure into human health observatories.

Openwater develops non-invasive, wearable systems that use light and sound to monitor and affect medical conditions in real-time. Their platform is open-source and designed for various clinical applications.

Helaina is focused on recreating human-identical proteins, starting with lactoferrin, to enhance nutrition and health outcomes. Their flagship product, effera™, is a bio-identical lactoferrin designed to be recognized by the human body, offering superior absorption and immune support.

KETOS provides automated water quality monitoring solutions that measure over 30 parameters in real-time, aimed at improving water safety and efficiency for industrial, agricultural, and municipal applications.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Invests in disruptive, technology-focused startups; established in 1999.

Invests at seed and early stages in purpose-driven, trailblazing entrepreneurs with unique ideas capable of reinventing entire industries. Focuses on companies founded by mission-driven founders building transformative technologies.

Refactor Capital is a solo GP venture fund where founders get direct access to Zal Bilimoria as the only decision-maker, applying software operator experience from Google, Netflix, and LinkedIn to hard tech sectors like aerospace, synthetic biology, and energy storage. The fund leads seed rounds with $1-2M checks targeting ~10% ownership across unusually broad hard-tech domains, backed by early hits like Solugen and Astranis.

Early-stage deep tech venture firm focused on helping entrepreneurs commercialize scientific and technological breakthroughs to build durable, impactful companies.